Although the overall results for cMET inhibitors in phase III clinical trials in non-small cell lung cancer are disappointing, subgroups of patients with MET gene alterations have been shown to benefit from cMET inhibitors17. This evidence concerns the gene MET and non-small cell lung carcinoma.